A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351
1. To determine the safety of combining gemtuzumab ozogamicin (GO) with CPX-351 and to determine maximal tolerated dose (MTD)/Recommended phase 2 dose (RP2D) of gemtuzumab ozogamicin with fixed dose of CPX-351;
2. To determine the rate of complete remission (CR) plus CR with incomplete count recovery (CRi);
3. To determine the rate of measurable residual disease via RT-PCR for core binding factor leukemia as well as NPM1 mutated AML;
4. To determine overall survival;
5. To determine relapse free survival.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged >18 and & > For females of child-bearing potential: use of highly effective contraception upon enrollment and during study participation and for an additional 6 months after the end of CPX-351 and Gemtuzumab ozogamicin administration: A female of child-bearing potential is considered when a sexually mature female: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months
The effects of CPX-351 and gemtuzumab ozogamicin on the developing human fetus are unknown. For this reason, women of child-bearing potential as defined above must have a negative serum or urine pregnancy test within 24 hours prior to beginning study treatment.
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
Myeloblasts expressing CD33 as determined by flow cytometry or immunohistochemistry
ECOG > Prior malignancy is allowed providing it does not require concurrent therapy. Exception: Active hormonal therapy is allowed.
Prior hypomethylating agents (HMA) therapy including azacitidine or decitabine when used for non-AML diagnoses is allowed. Most recent dose must have been >14 days prior to day 1 of study treatment.
Participants must have acceptable organ function
Adequate cardiac function defined as ejection fraction of >50% as determined by multigated acquisition scan (MUGA) or 2D echocardiogram.
Hydroxyurea is allowed for cytoreduction until day 1 of study treatment
Prior treatment of AML except hydroxyurea and/or leukapheresis
Participants with adverse risk AML as defined by ELN 2017 criteria
Participants with acute promyelocytic leukemia (APL).
Known clinically active central nervous system (CNS) leukemia.
Severe liver disease (cirrhosis, non-alcoholic steatohepatitis, sclerosing cholangitis) or patients with known Wilson's disease.
Participants with known active infection with hepatitis B or hepatitis C virus
Known allergic reactions to components of the CPX-351 (cytarabine or daunorubicin) or Gemtuzumab ozogamicin.
Patients with any prior anthracycline exposure plus any planned on-study anthracycline exposure cannot not exceed 550 mg/m2 of daunorubicin (or equivalent). For participants who have received radiation therapy to the mediastinum, the total cumulative dose of anthracycline should not exceed 400 mg/m2 of daunorubicin(or equivalent).
Hemodynamically unstable (subjects requiring vasopressor support will not be eligible).
Treatment with another investigational drug within 14 days.
Uncontrolled cardiac disease including congestive heart failure class III or IV by the NYHA, unstable angina (angina symptoms at rest), new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
Any disorder that compromises the subject's ability to give written informed consent and/or to comply with study procedures.
Any substance abuse, severe and/or uncontrolled medical, social or psychiatric conditions that may prevent the subject from completing the study, interfere with the evaluation of safety and/or efficacy, or interfere with the interpretation of the study results.
Female subject who is pregnant or breastfeeding.
Any patient with a known FLT3 ITD or FLT3 TKD mutation
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub